v3.26.3
Collaborative Research and Development Agreements - Narrative (Details)
 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2025
USD ($)
Nov. 24, 2023
USD ($)
Oct. 23, 2020
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Milestone
Dec. 31, 2024
USD ($)
Milestone
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           $ 53,044,000 $ 50,034,000   $ 234,603,000 $ 91,280,000
Other (expense) income, net           (1,000) 5,453,000   5,453,000 0
GSK | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           0     $ 125,000,000 $ 40,000,000
Number of milestone | Milestone                 2 2
Annual sales milestone threshold                   $ 500,000,000
GSK | JEMPERLI Royalty Monetization Agreement                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           51,200,000 96,000,000 $ 47,400,000 $ 96,000,000 47,400,000
GSK | Zejula Royalty Monetization Agreement                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           1,600,000 3,900,000 3,900,000 3,900,000 3,900,000
GSK | Jemperli Royalty Monetization Agreement, Milestone One                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue                   75,000,000
GSK | Jemperli Royalty Monetization Agreement, Milestone One | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue                 50,000,000  
Annual sales milestone threshold                 750,000,000 250,000,000
GSK | Jemperli Royalty Monetization Agreement, Milestone Two | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Annual sales milestone threshold                 1,000,000,000 $ 500,000,000,000
GSK | Fourth commercial sales milestone | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue       $ 75,000,000         75,000,000  
GSK | Phase 3 clinical trial initiation - first indication | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue         $ 5,000,000          
GSK | Royalty Agreement                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           52,800,000 $ 99,900,000 $ 51,300,000    
GSK | Royalty Agreement, up To $1. 0 billion | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Royalty percent on net sales     8.00%              
Royalty sales     $ 1,000,000,000              
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Royalty percent on net sales     12.00%              
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | PD-1 (Jemperli/Dostarlimab) | Minimum                    
Disaggregation of Revenue [Line Items]                    
Royalty sales     $ 1,000,000,000              
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | PD-1 (Jemperli/Dostarlimab) | Maximum                    
Disaggregation of Revenue [Line Items]                    
Royalty sales     $ 1,500,000,000              
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Royalty percent on net sales     20.00%              
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | PD-1 (Jemperli/Dostarlimab) | Minimum                    
Disaggregation of Revenue [Line Items]                    
Royalty sales     $ 1,500,000,000              
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | PD-1 (Jemperli/Dostarlimab) | Maximum                    
Disaggregation of Revenue [Line Items]                    
Royalty sales     $ 2,500,000,000              
GSK | Royalty Agreement, above $2.5 billion | PD-1 (Jemperli/Dostarlimab)                    
Disaggregation of Revenue [Line Items]                    
Royalty percent on net sales     25.00%              
Royalty sales     $ 2,500,000,000              
Centessa | Collaborative Arrangement [Member]                    
Disaggregation of Revenue [Line Items]                    
Potential future payments   $ 10,000,000       10        
Centessa | Collaborative Arrangement [Member] | License Agreement, Centessa Pharmaceuticals (UK) Limited                    
Disaggregation of Revenue [Line Items]                    
Cash payment   4,000,000                
Reimbursement   3,000,000                
Transaction costs incurred   300,000                
Total transaction   $ 7,300,000                
Vanda | Commercial Sales Milestone [Member]                    
Disaggregation of Revenue [Line Items]                    
Royalty sales           $ 100,000,000        
Vanda | Exclusive License Agreement                    
Disaggregation of Revenue [Line Items]                    
Royalty percent on net sales           10.00%        
Upfront payment           $ 15,000,000        
Transaction costs expensed                 2,500,000  
Vanda | Exclusive License Agreement | License                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           0     9,500,000  
Upfront payment $ 10,000,000                  
Vanda | Exclusive License Agreement | Transaction Service                    
Disaggregation of Revenue [Line Items]                    
Collaboration revenue           200,000     200,000  
Vanda | Exclusive License Agreement | Drug Supply                    
Disaggregation of Revenue [Line Items]                    
Upfront payment           $ 5,000,000     $ 5,400,000